Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dienogest versus placebo for symptomatic uterine fibroids
PACTR202512770428919Phase 2Not yet recruiting
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dienogest in Fibromyoma (LM). Primary endpoint: Change in leiomyoma volume. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dienogest
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on PACTR202512770428919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202512770428919.